NASS News: elliquence and Implanet Partner for Ultrasonic Bone Scalpel

Elliquence, a company specializing in advanced minimally invasive surgical technologies, and Implanet, a medical technology company specializing in implants for orthopedic surgery and the distribution of advanced medical equipment, have entered a strategic agreement for the distribution of Implanet’s Ultrasonic Bone Scalpel in endoscopic spine surgery.
 
The announcement was made at the North American Spine Society (NASS) Annual Meeting, where both companies were on display.
 
“We’re honored to be engaging with our like-minded colleagues to further introduce the surgeon community to first-of-its-kind endoscopic blade technology,” stated Max Painter, Vice President and General Manager of Implanet America. “It’s rewarding to be able to team with other innovation-driven companies to expand the reach of this innovative technology and provide the broader surgeon community with game-changing solutions.”
 
elliquence’s Surgi-Max Ultra platform is recognized for delivering effective soft tissue dissection and coagulation in endoscopic procedures, while Implanet’s Olea technology enables precise and efficient bone cutting. 
 
surgeons are now equipped with a unique synergy of bone and soft tissue management tools through the combination of Implanet’s ultrasonic bone scalpel with elliquence’s Surgi-Max Ultra radiofrequency and its bipolar Trigger-Flex technology. 
 
Integrating the ultrasonic bone scalpel allows for safer, more controlled bone removal, preserving neural structures and minimizing soft tissue damage—further enhancing the precision and outcomes of minimally invasive spine surgery.
 
“This partnership is an endorsement of the clinical value of our technology,” added Ludovic Lastennet, Implanet’s Chief Executive Officer. “This type of partnership fits with the medium-term development plan we announced in the middle of 2023 and the partnership with SanYou Medical. It demonstrates our ability to market new technologies with a newly formed seasoned team in the US. With this team on board, we will be able to launch new mainstream product lines in the short term.”